Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833

Judith van Asperen(University of Groningen), Jos H. Beijnen(The Netherlands Cancer Institute), Piet Borst(The Netherlands Cancer Institute), Olaf van Tellingen(Dutch Cancer Society), Alex Sparreboom(The Ohio State University), Alfred H. Schinkel(Oncode Institute), W J Nooijen
British Journal of Cancer
November 1, 1997
10.1038/bjc.1997.530
Cited by 203

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884